Clinical Edge Journal Scan

Plasma glutamate level: A potential indicator for episodic and chronic migraines


 

Key clinical point: Interictal levels of plasma glutamate are elevated in patients with episodic migraine (EM) and chronic migraine (CM), thus qualifying it as a potential marker for both EM and CM.

Major finding: Plasma glutamate levels were significantly higher in patients with EM (49.73 μmol/L [95% CI 40.82-66.12] ) and CM (58.70 μmol/L [95% CI 44.64-72.46]) vs control participants (38.79 μmol/L [95% CI 29.50-53.60]; P < .001).

Study details: This single-center study included 240 women aged 19-65 years, of which 98 had EM, 92 had CM, and 50 were nonmigraine control participants.

Disclosures: The study was supported by a National Research Foundation of Korea (NRF) grant from the Korean government. MK Chu declared serving as a site investigator for a multicenter trial and an advisory member for and receiving lecture honoraria and grants from various organizations, including NRF.

Source: Park CG, Chu MK. Interictal plasma glutamate levels are elevated in individuals with episodic and chronic migraine. Sci Rep. 2022;12:6921 (Apr 28). Doi: 10.1038/s41598-022-10883-9

Recommended Reading

CGRPs: They’ve Been a Long Time Coming
Migraine ICYMI
Safety Concerns with CGRP Monoclonal Antibodies
Migraine ICYMI
Fremanezumab can prevent migraine across a broad real-world patient population
Migraine ICYMI
Evidence of real-world effectiveness of erenumab against chronic migraine
Migraine ICYMI
Migraine: Suboptimal first-dose responders may benefit from a second dose of eptinezumab
Migraine ICYMI
Galcanezumab reduces acute headache medication use in treatment-resistant migraine
Migraine ICYMI
Migraine: Ubrogepant therapy yields favorable 2-hour outcomes in triptan insufficient responders
Migraine ICYMI
Subcutaneous injection of diclofenac sodium is effective against acute migraine
Migraine ICYMI
Is migraine related to adverse pregnancy outcomes?
Migraine ICYMI
Patients with migraine show high adherence and persistence to fremanezumab in a real-world setting
Migraine ICYMI